Tina Shaffaf1,2, Ebrahim Ghafar-Zadeh1,2,3. 1. Biologically Inspired Sensors and Actuators Laboratory (BioSA), York University, Toronto, ON M3J1P3, Canada. 2. Department of Biology, Faculty of Science, York University, Toronto, ON M3J1P3, Canada. 3. Department of Electrical Engineering and Computer Science, Lassonde School of Engineering, York University, Toronto, ON M3J1P3, Canada.
Abstract
After the initiation of the current outbreak, humans' lives have been profoundly impacted by COVID-19. During the first months, no rapid and reliable detecting tool was readily available to sufficiently respond to the requirement of massive testing. In this situation, when the development of an effective vaccine requires at least a few months, it is crucial to be prepared by developing and commercializing affordable, accurate, rapid and adaptable biosensors not only to fight Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) but also to be armed to avoid the pandemic in the earliest stages in the future. The COVID-19 diagnostic tools are categorized into two main groups of Nucleic Acid (NA)-based and protein-based tests. To date, nucleic acid-based detection has been announced as the gold-standard strategy for coronavirus detection; however, protein-based tests are promising alternatives for rapid and large-scale screening of susceptible groups. In this review, we discuss the current protein-based biosensing tools, the research advances and the potential protein-detecting strategies for COVID-19 detection. This narrative review aims to highlight the importance of the diagnostic tests, encourage the academic research groups and the companies to eliminate the shortcomings of the current techniques and step forward to mass-producing reliable point-of-care (POC) and point-of-need (PON) adaptable diagnostic tools for large-scale screening in the future outbreaks.
After the initiation of the current outbreak, humans' lives have beeene">n profouene">ndly impacted by n class="Disease">COVID-19. During the first months, no rapid and reliable detecting tool was readily available to sufficiently respond to the requirement of massive testing. In this situation, when the development of an effective vaccine requires at least a few months, it is crucial to be prepared by developing and commercializing affordable, accurate, rapid and adaptable biosensors not only to fight Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) but also to be armed to avoid the pandemic in the earliest stages in the future. The COVID-19 diagnostic tools are categorized into two main groups of Nucleic Acid (NA)-based and protein-based tests. To date, nucleic acid-based detection has been announced as the gold-standard strategy for coronavirus detection; however, protein-based tests are promising alternatives for rapid and large-scale screening of susceptible groups. In this review, we discuss the current protein-based biosensing tools, the research advances and the potential protein-detecting strategies for COVID-19 detection. This narrative review aims to highlight the importance of the diagnostic tests, encourage the academic research groups and the companies to eliminate the shortcomings of the current techniques and step forward to mass-producing reliable point-of-care (POC) and point-of-need (PON) adaptable diagnostic tools for large-scale screening in the future outbreaks.
Authors: Daniel Wrapp; Nianshuang Wang; Kizzmekia S Corbett; Jory A Goldsmith; Ching-Lin Hsieh; Olubukola Abiona; Barney S Graham; Jason S McLellan Journal: Science Date: 2020-02-19 Impact factor: 47.728
Authors: Mei San Tang; Karl G Hock; Nicole M Logsdon; Jennifer E Hayes; Ann M Gronowski; Neil W Anderson; Christopher W Farnsworth Journal: Clin Chem Date: 2020-08-01 Impact factor: 8.327
Authors: Beatriz Araujo Oliveira; Lea Campos de Oliveira; Franciane Mendes de Oliveira; Geovana Maria Pereira; Regina Maia de Souza; Erika Regina Manuli; Fabricio Klerynton Marchini; Evelyn Patrícia Sanchez Espinoza; Marcelo Park; Leandro Taniguchi; Pedro Vitale Mendes; Lucas Augusto Moyses Franco; Ana Catharina Nastri; Maura Salaroli de Oliveira; José Mauro Vieira Junior; Esper Georges Kallas; Anna Sara Levin; Ester Cerdeira Sabino; Silvia Figueiredo Costa Journal: Rev Inst Med Trop Sao Paulo Date: 2022-09-30 Impact factor: 2.169